<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-D3F5O8IC/42bbaf63-53af-458b-ba42-fb787632289c/PDF"><dcterms:extent>21423 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-D3F5O8IC/3e627f6d-814b-4255-ba15-9418b926e91b/TEXT"><dcterms:extent>0 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1992-2025"><edm:begin xml:lang="en">1992</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-D3F5O8IC"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:SPR-WQVGMCSC" /><dcterms:issued>2025</dcterms:issued><dc:creator>Bukhari, Agussalim</dc:creator><dc:creator>Christopher, Paulus Mario</dc:creator><dc:creator>Djawad, Khairuddin</dc:creator><dc:creator>Irawan Anwar, Anis</dc:creator><dc:creator>Kapantow, Marlyn Grace</dc:creator><dc:creator>Mawu, Ferra Olivia</dc:creator><dc:contributor>Mawu, Ferra Olivia</dc:contributor><dc:format xml:lang="sl">letnik:34</dc:format><dc:format xml:lang="sl">številka:iss. 3</dc:format><dc:format xml:lang="sl">str. 95-99</dc:format><dc:identifier>DOI:10.15570/actaapa.2025.23</dc:identifier><dc:identifier>ISSN:1318-4458</dc:identifier><dc:identifier>COBISSID_HOST:260313347</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-D3F5O8IC</dc:identifier><dc:language>en</dc:language><dc:publisher xml:lang="sl">Slovene Welding Society</dc:publisher><dcterms:isPartOf xml:lang="sl">Acta dermatovenerologica Alpina, Pannonica et Adriatica</dcterms:isPartOf><dc:subject xml:lang="en">acne vulgaris</dc:subject><dc:subject xml:lang="sl">akne vulgaris</dc:subject><dc:subject xml:lang="sl">dušikov oksid</dc:subject><dc:subject xml:lang="en">glutathione</dc:subject><dc:subject xml:lang="sl">glutation</dc:subject><dc:subject xml:lang="en">interleukin-1?</dc:subject><dc:subject xml:lang="sl">interlevkin-1?</dc:subject><dc:subject xml:lang="en">nitric oxide</dc:subject><dc:subject xml:lang="sl">oksidativni stres</dc:subject><dc:subject xml:lang="en">oxidative stress</dc:subject><dcterms:temporal rdf:resource="1992-2025" /><dc:title xml:lang="sl">Effectiveness of oral glutathione in reducing nitric oxide and IL-1? concentrations for clinical improvement in mild to moderate acne vulgaris:| a randomized controlled trial|</dc:title><dc:description xml:lang="sl">Introduction: Acne vulgaris (AV) is a chronic inflammatory dermatosis predominantly affecting adolescents and young adults. Oxidative and nitrosative stress, marked by elevated nitric oxide (NO) and interleukin (IL)-1?, contributes to AV pathogenesis. Glutathione, a key antioxidant, may attenuate oxidative and nitrosative stress and modulate inflammatory pathways. This study investigates the effectiveness of oral glutathione supplementation on serum NO and IL-1? concentrations, and clinical improvement in mild to moderate AV patients. Methods: A randomized controlled trial was conducted involving 40 subjects diagnosed with mild to moderate AV. Participants were randomized to receive either 500 mg oral glutathione (n = 22) or placebo (n = 18) once daily for 4 weeks. Clinical severity of AV was assessed utilizing the Lehmann criteria. Serum levels of NO and IL-1? were measured at baseline and week 4. Results: At week 4, reductions in serum NO and IL-1? concentrations were observed in the glutathione group; however, these changes did not reach statistical significance (p &gt; 0.05). Clinical improvement occurred in seven subjects (31.8%) in the glutathione group, with a reduction from moderate to mild severity. No adverse reactions were reported. Conclusions: Oral glutathione supplementation demonstrated a non-significant trend toward reducing oxidative and nitrosative stress markers and improving mild to moderate AV. Further studies are recommended to validate these findings</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-D3F5O8IC"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-D3F5O8IC" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-D3F5O8IC/42bbaf63-53af-458b-ba42-fb787632289c/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Združenje slovenskih dermatovenerologov</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-D3F5O8IC/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-D3F5O8IC" /></ore:Aggregation></rdf:RDF>